tracken
Immunocore Holdings plc - ADR Aktie News
Positiv
Barrons
●
2 Tage alt
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
Neutral
GlobeNewsWire
●
19 Tage alt
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIR...
Neutral
GlobeNewsWire
●
etwa ein Monat alt
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Positiv
InvestorPlace
●
2 Monate alt
Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.
Neutral
GlobeNewsWire
●
3 Monate alt
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Neutral
GlobeNewsWire
●
3 Monate alt
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Neutral
Seeking Alpha
●
3 Monate alt
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
